Pfizer
Vaishali Sahasrabudhe has over 29 years of experience in the pharmaceutical industry, with a significant tenure at Pfizer from January 2002 to March 2025, where roles included Vice President and Global Head of Pharmacometrics and Systems Pharmacology, Vice President and Head of Clinical Pharmacology in Translational Clinical Sciences, and Clinical Pharmacology TA Head for Internal Medicine. Prior to joining Pfizer, Vaishali served as a Senior Research Investigator at Bristol-Myers Squibb from January 1996 to December 2001. Educational background includes a degree from The University of Texas at Austin (January 1991 - January 1996) and earlier studies at The Bombay College of Pharmacy (January 1987 - January 1991).
This person is not in any teams
This person is not in any offices
Pfizer
616 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.